Gene | Associated with SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME in | Link to HGNC | Cytogenetic band | Number of associated diseases | Associated diseases |
---|---|---|---|---|---|
HRAS | ClinVar, OMIM, HUMSAVAR | HGNC link | 11p15.5 | 6 | 218040, 137550, 185500, 109800, 163200, 162900 |
NRAS | ClinVar, OMIM | HGNC link | 1p13.2 | 8 | 137550, PS163950, 249400, 163200, 607785, 114500, 614470, 162900 |
KRAS | ClinVar, OMIM | HGNC link | 12p12.1 | 14 | 601626, 600268, 137215, 109800, PS163950, 211980, 114480, PS115150, 613659, 163200, 607785, 614470, 162900, 260350 |
Download the disease annotation in CSV format
regulated gene | associated to this disease | # TFs | TFs | # TFs associated with this disease | TFs associated with this disease |
---|---|---|---|---|---|
HRAS | YES | 3 | SP1, MAZ, TP53 | 0 | |
NRAS | YES | 1 | AR | 0 | |
KRAS | YES | 1 | MYC | 0 |
Gene1 | Gene2 | Direct Interaction | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|
HRAS | NRAS | No | 7 | RAP1GDS1, RABGGTB, MLLT4, RAF1, PIK3CG, RGL2, TMEM185A |
HRAS | KRAS | No | 10 | RALGDS, RASSF5, RGL2, IL24, PIK3CA, BTRC, RAF1, PIK3CG, RAP1GDS1, SHOC2 |
NRAS | KRAS | No | 6 | RGL2, RAP1GDS1, ELAVL1, PIK3CG, RAF1, EEF1A1 |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct Interaction | Interaction mode | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|---|
HRAS | KRAS | Yes | binding | 111 | RASA1, AKT1, RASSF4, TP53, MAP3K2, PIK3CA, EGFR, GAST, NCAM1, YWHAB, SPTAN1, PPARD, PTK2, MAPK14, RET, CALM1, SLC3A2, MAPK13, RPS6KB1, JUN, ETS2, ABL1, SPTBN5, CCR5, TNS4, MAPK3, BTRC, MTOR, FRS2, MAZ, MAP3K3, ARAF, KSR2, IL8, LGALS3, JUND, RASGRP3, SPTBN1, DDX43, TEK, KSR1, CNKSR3, SHC3, RGL4, NPM1, GRB2, RASGRF2, MAP3K19, RALGDS, SPTA1, RASA2, CDX1, SPRY2, UBC, MLLT4, MAP2K2, BMP4, NT5E, SPTBN4, HBEGF, FYN, RGL1, RASSF2, MAPK11, CCND1, SHC2, ERBB3, ETS1, RAF1, SHOC2, KIT, LGALS1, PTPRA, VEGFA, MAPK12, YES1, MGMT, SPTB, MEN1, RASGRP1, RASA3, PIK3CD, MDM4, PTPN11, PIK3CG, IGF2BP1, ANGPT1, ITSN1, MAP2K1, SOS1, EPHA2, ERBB2, MECOM, SHC1, MAPK7, NCL, AKT2, CDX2, SPTBN2, EGF, RASSF7, SRC, BCL2L11, NOTCH1, BCL2, MAPK1, PIK3CB, IRS1, IRS2, BRAF, ERBB4 |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct Interaction | Complexes | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|---|
HRAS | NRAS | Yes | RAF1-RAS complex, EGF induced | 2 | KRAS, RAF1 |
HRAS | KRAS | Yes | RAF1-RAS complex, EGF induced | 2 | NRAS, RAF1 |
NRAS | KRAS | Yes | RAF1-RAS complex, EGF induced | 2 | HRAS, RAF1 |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct interaction | More information |
---|---|---|---|
HRAS | KRAS | No | |
HRAS | NRAS | maybe, indirect | They are member of the same protein family. |
KRAS | NRAS | maybe, indirect | They are members of the same protein family. |
KEGG term | KEGG term ID | IC | Number of genes with the same term | Genes |
---|---|---|---|---|
Signaling pathways regulating pluripotency of stem cells | hsa04550 | 5.6 | 3 | HRAS, KRAS, NRAS |
Bladder cancer | hsa05219 | 7.38 | 3 | HRAS, KRAS, NRAS |
Endometrial cancer | hsa05213 | 6.81 | 3 | HRAS, KRAS, NRAS |
Renal cell carcinoma | hsa05211 | 6.6 | 3 | HRAS, KRAS, NRAS |
Thyroid cancer | hsa05216 | 7.48 | 3 | HRAS, KRAS, NRAS |
Melanoma | hsa05218 | 6.56 | 3 | HRAS, KRAS, NRAS |
Glioma | hsa05214 | 6.66 | 3 | HRAS, KRAS, NRAS |
Prostate cancer | hsa05215 | 6.11 | 3 | HRAS, KRAS, NRAS |
Tight junction | hsa04530 | 5.53 | 3 | HRAS, KRAS, NRAS |
Long-term potentiation | hsa04720 | 6.64 | 3 | HRAS, KRAS, NRAS |
Neurotrophin signaling pathway | hsa04722 | 5.78 | 3 | HRAS, KRAS, NRAS |
Cholinergic synapse | hsa04725 | 5.88 | 3 | HRAS, KRAS, NRAS |
Choline metabolism in cancer | hsa05231 | 6.09 | 3 | HRAS, KRAS, NRAS |
FoxO signaling pathway | hsa04068 | 5.63 | 3 | HRAS, KRAS, NRAS |
Serotonergic synapse | hsa04726 | 5.84 | 3 | HRAS, KRAS, NRAS |
Chemokine signaling pathway | hsa04062 | 5.19 | 3 | HRAS, KRAS, NRAS |
Oxytocin signaling pathway | hsa04921 | 5.4 | 3 | HRAS, KRAS, NRAS |
Rap1 signaling pathway | hsa04015 | 4.97 | 3 | HRAS, KRAS, NRAS |
Natural killer cell mediated cytotoxicity | hsa04650 | 5.53 | 3 | HRAS, KRAS, NRAS |
HTLV-I infection | hsa05166 | 4.59 | 3 | HRAS, KRAS, NRAS |
PI3K-Akt signaling pathway | hsa04151 | 4.21 | 3 | HRAS, KRAS, NRAS |
Hepatitis C | hsa05160 | 5.68 | 3 | HRAS, KRAS, NRAS |
Hepatitis B | hsa05161 | 5.52 | 3 | HRAS, KRAS, NRAS |
Chronic myeloid leukemia | hsa05220 | 6.48 | 3 | HRAS, KRAS, NRAS |
Gap junction | hsa04540 | 6.24 | 3 | HRAS, KRAS, NRAS |
VEGF signaling pathway | hsa04370 | 6.77 | 3 | HRAS, KRAS, NRAS |
Proteoglycans in cancer | hsa05205 | 5.02 | 3 | HRAS, KRAS, NRAS |
MicroRNAs in cancer | hsa05206 | 5.38 | 3 | HRAS, KRAS, NRAS |
Pathways in cancer | hsa05200 | 3.98 | 3 | HRAS, KRAS, NRAS |
Viral carcinogenesis | hsa05203 | 5.08 | 3 | HRAS, KRAS, NRAS |
GnRH signaling pathway | hsa04912 | 6.18 | 3 | HRAS, KRAS, NRAS |
Insulin signaling pathway | hsa04910 | 5.55 | 3 | HRAS, KRAS, NRAS |
Ras signaling pathway | hsa04014 | 4.9 | 3 | HRAS, KRAS, NRAS |
Melanogenesis | hsa04916 | 5.97 | 3 | HRAS, KRAS, NRAS |
ErbB signaling pathway | hsa04012 | 6.15 | 3 | HRAS, KRAS, NRAS |
Acute myeloid leukemia | hsa05221 | 6.74 | 3 | HRAS, KRAS, NRAS |
Estrogen signaling pathway | hsa04915 | 6.11 | 3 | HRAS, KRAS, NRAS |
Thyroid hormone signaling pathway | hsa04919 | 5.82 | 3 | HRAS, KRAS, NRAS |
Long-term depression | hsa04730 | 6.74 | 3 | HRAS, KRAS, NRAS |
Regulation of actin cytoskeleton | hsa04810 | 4.9 | 3 | HRAS, KRAS, NRAS |
T cell receptor signaling pathway | hsa04660 | 6.01 | 3 | HRAS, KRAS, NRAS |
Non-small cell lung cancer | hsa05223 | 6.88 | 3 | HRAS, KRAS, NRAS |
MAPK signaling pathway | hsa04010 | 4.63 | 3 | HRAS, KRAS, NRAS |
B cell receptor signaling pathway | hsa04662 | 6.52 | 3 | HRAS, KRAS, NRAS |
Alcoholism | hsa05034 | 5.59 | 3 | HRAS, KRAS, NRAS |
Axon guidance | hsa04360 | 5.63 | 3 | HRAS, KRAS, NRAS |
Central carbon metabolism in cancer | hsa05230 | 6.7 | 3 | HRAS, KRAS, NRAS |
Fc epsilon RI signaling pathway | hsa04664 | 6.6 | 3 | HRAS, KRAS, NRAS |
Prolactin signaling pathway | hsa04917 | 6.6 | 3 | HRAS, KRAS, NRAS |
REACTOME term | REACTOME term ID | IC | Number of genes with the same term | Genes |
---|---|---|---|---|
Interleukin-2 signaling | R-HSA-451927 | 5.05 | 3 | HRAS, KRAS, NRAS |
Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.62 | 3 | HRAS, KRAS, NRAS |
Developmental Biology | R-HSA-1266738 | 3.48 | 3 | HRAS, KRAS, NRAS |
Signaling by VEGF | R-HSA-194138 | 4.66 | 3 | HRAS, KRAS, NRAS |
FCERI mediated MAPK activation | R-HSA-2871796 | 4.32 | 3 | HRAS, KRAS, NRAS |
IRS-mediated signalling | R-HSA-112399 | 4.87 | 3 | HRAS, KRAS, NRAS |
Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 8.73 | 3 | HRAS, KRAS, NRAS |
Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 9.08 | 3 | HRAS, KRAS, NRAS |
Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 9.08 | 3 | HRAS, KRAS, NRAS |
VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.7 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR1 in disease | R-HSA-5655302 | 7.81 | 3 | HRAS, KRAS, NRAS |
Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 | 3 | HRAS, KRAS, NRAS |
SOS-mediated signalling | R-HSA-112412 | 5.15 | 3 | HRAS, KRAS, NRAS |
Tie2 Signaling | R-HSA-210993 | 8.81 | 3 | HRAS, KRAS, NRAS |
Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 | 3 | HRAS, KRAS, NRAS |
SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 8.46 | 3 | HRAS, KRAS, NRAS |
VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.07 | 3 | HRAS, KRAS, NRAS |
Immune System | R-HSA-168256 | 2.37 | 3 | HRAS, KRAS, NRAS |
Frs2-mediated activation | R-HSA-170968 | 5.12 | 3 | HRAS, KRAS, NRAS |
Downstream signal transduction | R-HSA-186763 | 4.65 | 3 | HRAS, KRAS, NRAS |
RAF activation | R-HSA-5673000 | 8.34 | 3 | HRAS, KRAS, NRAS |
RAF/MAP kinase cascade | R-HSA-5673001 | 5.15 | 3 | HRAS, KRAS, NRAS |
Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.12 | 3 | HRAS, KRAS, NRAS |
FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.14 | 3 | HRAS, KRAS, NRAS |
FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.14 | 3 | HRAS, KRAS, NRAS |
FRS-mediated FGFR3 signaling | R-HSA-5654706 | 5.14 | 3 | HRAS, KRAS, NRAS |
SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 8.81 | 3 | HRAS, KRAS, NRAS |
Activation of RAS in B cells | R-HSA-1169092 | 10.66 | 3 | HRAS, KRAS, NRAS |
Signaling by EGFR in Cancer | R-HSA-1643713 | 8.73 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR in disease | R-HSA-1226099 | 7.49 | 3 | HRAS, KRAS, NRAS |
Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 | 3 | HRAS, KRAS, NRAS |
Interleukin receptor SHC signaling | R-HSA-912526 | 5.09 | 3 | HRAS, KRAS, NRAS |
Innate Immune System | R-HSA-168249 | 3.17 | 3 | HRAS, KRAS, NRAS |
Signaling by ERBB2 | R-HSA-1227986 | 4.66 | 3 | HRAS, KRAS, NRAS |
SHC-related events triggered by IGF1R | R-HSA-2428933 | 9.81 | 3 | HRAS, KRAS, NRAS |
NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 | 3 | HRAS, KRAS, NRAS |
Prolonged ERK activation events | R-HSA-169893 | 5.11 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR2 | R-HSA-5654738 | 4.68 | 3 | HRAS, KRAS, NRAS |
GRB2 events in EGFR signaling | R-HSA-179812 | 5.15 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR1 | R-HSA-5654736 | 4.69 | 3 | HRAS, KRAS, NRAS |
DAP12 interactions | R-HSA-2172127 | 4.56 | 3 | HRAS, KRAS, NRAS |
EGFR Transactivation by Gastrin | R-HSA-2179392 | 9.81 | 3 | HRAS, KRAS, NRAS |
Axon guidance | R-HSA-422475 | 3.93 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR2 in disease | R-HSA-5655253 | 8.23 | 3 | HRAS, KRAS, NRAS |
Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.26 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR3 in disease | R-HSA-5655332 | 8.52 | 3 | HRAS, KRAS, NRAS |
Signaling by Leptin | R-HSA-2586552 | 5.1 | 3 | HRAS, KRAS, NRAS |
MAP2K and MAPK activation | R-HSA-5674135 | 7.66 | 3 | HRAS, KRAS, NRAS |
IGF1R signaling cascade | R-HSA-2428924 | 4.85 | 3 | HRAS, KRAS, NRAS |
IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.85 | 3 | HRAS, KRAS, NRAS |
Signaling by Insulin receptor | R-HSA-74752 | 4.73 | 3 | HRAS, KRAS, NRAS |
Disease | R-HSA-1643685 | 3.33 | 3 | HRAS, KRAS, NRAS |
Insulin receptor signalling cascade | R-HSA-74751 | 4.85 | 3 | HRAS, KRAS, NRAS |
Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 | 3 | HRAS, KRAS, NRAS |
SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 8.59 | 3 | HRAS, KRAS, NRAS |
Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.59 | 3 | HRAS, KRAS, NRAS |
C-type lectin receptors (CLRs) | R-HSA-5621481 | 6.06 | 3 | HRAS, KRAS, NRAS |
Diseases of signal transduction | R-HSA-5663202 | 4.89 | 3 | HRAS, KRAS, NRAS |
GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.15 | 3 | HRAS, KRAS, NRAS |
Signalling to RAS | R-HSA-167044 | 5.08 | 3 | HRAS, KRAS, NRAS |
SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 8.28 | 3 | HRAS, KRAS, NRAS |
Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 | 3 | HRAS, KRAS, NRAS |
SHC1 events in EGFR signaling | R-HSA-180336 | 5.15 | 3 | HRAS, KRAS, NRAS |
FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.14 | 3 | HRAS, KRAS, NRAS |
SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.15 | 3 | HRAS, KRAS, NRAS |
Signaling by EGFR | R-HSA-177929 | 4.59 | 3 | HRAS, KRAS, NRAS |
ARMS-mediated activation | R-HSA-170984 | 5.12 | 3 | HRAS, KRAS, NRAS |
CD209 (DC-SIGN) signaling | R-HSA-5621575 | 8.59 | 3 | HRAS, KRAS, NRAS |
SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.15 | 3 | HRAS, KRAS, NRAS |
Signaling by PDGF | R-HSA-186797 | 4.53 | 3 | HRAS, KRAS, NRAS |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.85 | 3 | HRAS, KRAS, NRAS |
p38MAPK events | R-HSA-171007 | 9.28 | 3 | HRAS, KRAS, NRAS |
Signaling by Interleukins | R-HSA-449147 | 4.71 | 3 | HRAS, KRAS, NRAS |
Cell surface interactions at the vascular wall | R-HSA-202733 | 6.32 | 3 | HRAS, KRAS, NRAS |
Cytokine Signaling in Immune system | R-HSA-1280215 | 3.74 | 3 | HRAS, KRAS, NRAS |
Signaling by ERBB4 | R-HSA-1236394 | 4.7 | 3 | HRAS, KRAS, NRAS |
MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.11 | 3 | HRAS, KRAS, NRAS |
Adaptive Immune System | R-HSA-1280218 | 3.19 | 3 | HRAS, KRAS, NRAS |
MAPK family signaling cascades | R-HSA-5683057 | 4.89 | 3 | HRAS, KRAS, NRAS |
Signalling by NGF | R-HSA-166520 | 4.23 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR4 | R-HSA-5654743 | 4.69 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR3 | R-HSA-5654741 | 4.69 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR | R-HSA-190236 | 4.67 | 3 | HRAS, KRAS, NRAS |
Signaling by SCF-KIT | R-HSA-1433557 | 4.73 | 3 | HRAS, KRAS, NRAS |
NCAM signaling for neurite out-growth | R-HSA-375165 | 4.9 | 3 | HRAS, KRAS, NRAS |
DAP12 signaling | R-HSA-2424491 | 4.64 | 3 | HRAS, KRAS, NRAS |
Interleukin-3, 5 and GM-CSF signaling | R-HSA-512988 | 4.99 | 3 | HRAS, KRAS, NRAS |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 8.73 | 3 | HRAS, KRAS, NRAS |
Negative regulation of MAPK pathway | R-HSA-5675221 | 7.66 | 3 | HRAS, KRAS, NRAS |
Regulation of RAS by GAPs | R-HSA-5658442 | 6.92 | 3 | HRAS, KRAS, NRAS |
Signaling by GPCR | R-HSA-372790 | 2.68 | 3 | HRAS, KRAS, NRAS |
Signalling to ERKs | R-HSA-187687 | 5.04 | 3 | HRAS, KRAS, NRAS |
Signaling by FGFR4 in disease | R-HSA-5655291 | 9.52 | 3 | HRAS, KRAS, NRAS |
Hemostasis | R-HSA-109582 | 3.98 | 3 | HRAS, KRAS, NRAS |
Signal Transduction | R-HSA-162582 | 1.78 | 3 | HRAS, KRAS, NRAS |
GO | IC | Number of genes with the same GO | Genes |
---|---|---|---|
intracellular membrane-bounded organelle (GO:0043231) | 0.6 | 3 | HRAS, KRAS, NRAS |
membrane (GO:0016020) | 0.68 | 3 | HRAS, KRAS, NRAS |
cell part (GO:0044464) | 0.11 | 3 | HRAS, KRAS, NRAS |
cytoplasmic part (GO:0044444) | 0.82 | 3 | HRAS, KRAS, NRAS |
intracellular (GO:0005622) | 2.37 | 3 | HRAS, KRAS, NRAS |
intracellular organelle (GO:0043229) | 0.51 | 3 | HRAS, KRAS, NRAS |
plasma membrane (GO:0005886) | 1.39 | 3 | HRAS, KRAS, NRAS |
intracellular part (GO:0044424) | 0.28 | 3 | HRAS, KRAS, NRAS |
membrane-bounded organelle (GO:0043227) | 0.47 | 3 | HRAS, KRAS, NRAS |
organelle (GO:0043226) | 0.4 | 3 | HRAS, KRAS, NRAS |
cytoplasm (GO:0005737) | 1.01 | 2 | HRAS, KRAS |
Golgi apparatus (GO:0005794) | 2.7 | 2 | HRAS, NRAS |
organelle membrane (GO:0031090) | 1.97 | 2 | HRAS, NRAS |
bounding membrane of organelle (GO:0098588) | 2.39 | 2 | HRAS, NRAS |
Golgi membrane (GO:0000139) | 3.28 | 2 | HRAS, NRAS |
intracellular organelle part (GO:0044446) | 0.81 | 2 | HRAS, NRAS |
Golgi apparatus part (GO:0044431) | 3.0 | 2 | HRAS, NRAS |
cytosol (GO:0005829) | 1.68 | 2 | HRAS, KRAS |
organelle part (GO:0044422) | 0.79 | 2 | HRAS, NRAS |
Term | New enriched term | IC | P value | Genes |
---|---|---|---|---|
protein kinase complex (GO:1902911) | NEW | 5.31 | 0.035 | HRAS, KRAS |
Golgi cisterna membrane (GO:0032580) | NEW | 5.5 | 0.048 | HRAS, KRAS |
endosomal part (GO:0044440) | NEW | 3.73 | 0.034 | HRAS, KRAS, NRAS |
endosome membrane (GO:0010008) | NEW | 3.83 | 0.03 | HRAS, KRAS, NRAS |